On September 27, the official website of the CDE showed that the application for the new indication of Pfize Crisaborole cream (Chinese trade name: Sultanming, English trade name: Eucris a, Staquis) was accepted, presumably for children and adults aged 3 months and older atopic dermatitis patients.

Crisaborole is a small-molecule, non-hormonal, nonsteroidal anti-inflammatory topical phosphodiesterase 4 (PDE-4) inhibitor developed by Anacor. In May 2016, Pfizer acquired the company for $5.2 billion and acquired the drug. In December of the same year, Crisaborole was approved by the FDA for marketing, becoming the first prescription drug for atopic dermatitis approved in 10 years, and the first nonsteroidal external drug to inhibit skin PDE4.

Crisaborole Inhibitors as a new drug, in fact, oral dosage forms have been used for moderate and severe plaque psoriasis and psoriatic arthritis, the main side effect is gastrointestinal discomfort, there is no other special stain.

Crisaborole as Topical drugs, less absorbed through the skin, the probability of this side effect of gastrointestinal discomfort is also reduced to a very low.

As a result, Crisaborole suddenly became the “hope of the whole village” since 15 years, doctors and parents have been eager to have a safe, effective and long-term use of topical drugs is too long.

How effective is the drug with Crisaborole?

In 2016, two Phase III clinical trial studies brought very exciting news, Crisaborole, a topical ointment of phosphodiesterase-4 (PDE4) inhibitors, for patients with atopic dermatitis over 2 years of age (children and adults), achieved good clinical results.